Delivery Order SPE2DB20D2104-SPE2DB26FLZZS
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Dupixent 300 mg/2 ml pens with a ceiling value of $13,120.76. This is a firm fixed-price delivery order with an ultimate completion date of September 2, 2025, and represents a non-competitive, open-market award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Dupixent 300 mg/2 mL pen injections with a ceiling value of $14,525.26. This firm fixed-price delivery order, which is expected to be completed by August 4, 2025, was competitively awarded with no set-aside designation. The product will be delivered to the prime contractor's location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $217,423.50 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 28, 2025. This firm fixed-price delivery order, which carries an ultimate completion date of July 29, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its Pennsylvania...
- The Defense Logistics Agency (DLA) awarded a $22,848.80 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent (dupilumab) 300 mg/2 mL pens. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is scheduled for completion by August 5, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $35,600.20 on August 29, 2025, for Dupixent 300 mg/2 mL pen auto-injectors. The contract is a firm fixed price delivery order with no set-aside designation, indicating competitive award, and is scheduled for completion by September 2, 2025. AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Dupixent 300 mg/2 ml pen injections (2 ml quantity) with a ceiling value of $21,486.82. This is a firm fixed price delivery order issued under a non-competitive, non-set-aside procurement. The order is set for ultimate completion by September 11, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,279.86 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 16, 2025, with a completion date of July 17, 2025. This firm fixed price delivery order was competitively awarded without a set-aside designation and will be performed at the vendor's corporate office in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various inflammatory conditions, including...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $11,758.26. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 8, 2025. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various inflammatory conditions,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,531.64 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL pen injectors on September 26, 2025. This non-competitive, firm fixed-price delivery order is set to be completed by September 29, 2025, with performance occurring at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical supply vendor,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,527.70 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 22, 2025, with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and specifies performance at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB26FLZZSDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on October 14, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $19,175.67. This is a firm fixed-price delivery order with no set-aside designation, issued competitively, and scheduled for completion by October 15, 2025. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026, serving as a comprehensive global pharmaceutical support vehicle for military healthcare programs. Dupixent (dupilumab) is a prescription biologic medication used to treat conditions including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a broad portfolio of brand-name and generic medications, vaccines, and medical supplies to support military and veteran healthcare systems, the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities. The firm fixed-price delivery order structure and AmerisourceBergen's established track record with DLA demonstrate the contractor's capability to meet federal pharmaceutical supply requirements through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.2k | 10/14/25 |